NO20033343L - Farmasöytiske doseringsformer av epothiloner for oral administrasjon - Google Patents

Farmasöytiske doseringsformer av epothiloner for oral administrasjon

Info

Publication number
NO20033343L
NO20033343L NO20033343A NO20033343A NO20033343L NO 20033343 L NO20033343 L NO 20033343L NO 20033343 A NO20033343 A NO 20033343A NO 20033343 A NO20033343 A NO 20033343A NO 20033343 L NO20033343 L NO 20033343L
Authority
NO
Norway
Prior art keywords
epothilones
dosage forms
oral administration
pharmaceutical dosage
pharmaceutical
Prior art date
Application number
NO20033343A
Other languages
English (en)
Norwegian (no)
Other versions
NO20033343D0 (no
Inventor
Rebanta Bandyopadhyay
Timothy M Malloy
Andrea Panaggio
Krishnaswamy Srinivas Raghavan
Sailesh Amilal Varia
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of NO20033343D0 publication Critical patent/NO20033343D0/no
Publication of NO20033343L publication Critical patent/NO20033343L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20033343A 2001-01-25 2003-07-24 Farmasöytiske doseringsformer av epothiloner for oral administrasjon NO20033343L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26422801P 2001-01-25 2001-01-25
US29001901P 2001-05-11 2001-05-11
PCT/US2002/002518 WO2002058701A1 (en) 2001-01-25 2002-01-25 Pharmaceutical dosage forms of epothilones for oral administration

Publications (2)

Publication Number Publication Date
NO20033343D0 NO20033343D0 (no) 2003-07-24
NO20033343L true NO20033343L (no) 2003-09-24

Family

ID=26950349

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20033343A NO20033343L (no) 2001-01-25 2003-07-24 Farmasöytiske doseringsformer av epothiloner for oral administrasjon

Country Status (26)

Country Link
US (2) US6576651B2 (sh)
EP (1) EP1361877A1 (sh)
JP (1) JP2004528287A (sh)
KR (1) KR20040025888A (sh)
CN (1) CN1268336C (sh)
AR (1) AR035078A1 (sh)
BG (1) BG108027A (sh)
BR (1) BR0206695A (sh)
CA (1) CA2434584A1 (sh)
CZ (1) CZ20032023A3 (sh)
EE (1) EE200300329A (sh)
HR (1) HRP20030674A2 (sh)
HU (1) HUP0303800A3 (sh)
IL (1) IL156759A0 (sh)
IS (1) IS6892A (sh)
MX (1) MXPA03006476A (sh)
NO (1) NO20033343L (sh)
NZ (1) NZ526871A (sh)
PE (1) PE20020853A1 (sh)
PL (1) PL368636A1 (sh)
RU (1) RU2291695C2 (sh)
SK (1) SK9212003A3 (sh)
TW (1) TWI250017B (sh)
UY (1) UY27138A1 (sh)
WO (2) WO2002058699A1 (sh)
YU (1) YU58103A (sh)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2273083C (en) * 1996-12-03 2012-09-18 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6867305B2 (en) 1996-12-03 2005-03-15 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6204388B1 (en) * 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US20050043376A1 (en) * 1996-12-03 2005-02-24 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
US6780620B1 (en) * 1998-12-23 2004-08-24 Bristol-Myers Squibb Company Microbial transformation method for the preparation of an epothilone
US6824879B2 (en) 1999-06-10 2004-11-30 Honeywell International Inc. Spin-on-glass anti-reflective coatings for photolithography
CA2374944A1 (en) 1999-06-10 2000-12-21 Nigel Hacker Spin-on-glass anti-reflective coatings for photolithography
US8618085B2 (en) * 2000-04-28 2013-12-31 Koasn Biosciences Incorporated Therapeutic formulations of desoxyepothilones
WO2002058699A1 (en) 2001-01-25 2002-08-01 Bristol-Myers Squibb Company Pharmaceutical forms of epothilones for oral administration
RU2003126171A (ru) * 2001-01-25 2005-02-27 Бристол-Маерс Сквибб Компани (Us) Парентеральный состав, содержащий аналоги эпотилона
MXPA03007394A (es) 2001-02-20 2003-12-04 Bristol Myers Squibb Co Tratamiento de tumores refractarios mediante uso de derivados de epotilona.
EP1383490B1 (en) * 2001-03-14 2012-04-25 Bristol-Myers Squibb Company Combination of an epothilone analog and chemotherapeutic agents for the treatment of proliferative diseases
WO2003044600A1 (en) 2001-11-15 2003-05-30 Honeywell International Inc. Spin-on anti-reflective coatings for photolithography
AU2003218107A1 (en) * 2002-03-12 2003-09-29 Bristol-Myers Squibb Company C12-cyano epothilone derivatives
TW200403994A (en) * 2002-04-04 2004-03-16 Bristol Myers Squibb Co Oral administration of EPOTHILONES
TW200400191A (en) * 2002-05-15 2004-01-01 Bristol Myers Squibb Co Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives
ATE350383T1 (de) 2002-08-23 2007-01-15 Sloan Kettering Inst Cancer Synthese von epothilonen, zwischenprodukte dafür, analoga und deren verwendungen
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
EP1551425A4 (en) * 2002-10-09 2006-09-20 Kosan Biosciences Inc THERAPEUTIC FORMULATIONS
US7390503B1 (en) 2003-08-22 2008-06-24 Barr Laboratories, Inc. Ondansetron orally disintegrating tablets
SI2172205T1 (sl) * 2003-08-26 2014-10-30 Shire Biopharmaceuticals Holdings Ireland Limited Farmacevtska formulacija obsegajoča lantanove spojine
US20050171167A1 (en) * 2003-11-04 2005-08-04 Haby Thomas A. Process and formulation containing epothilones and analogs thereof
ES2393674T3 (es) * 2003-11-14 2012-12-27 Brigham And Women's Hospital, Inc. Métodos para modular la inmunidad
US8053159B2 (en) 2003-11-18 2011-11-08 Honeywell International Inc. Antireflective coatings for via fill and photolithography applications and methods of preparation thereof
US20090004277A1 (en) * 2004-05-18 2009-01-01 Franchini Miriam K Nanoparticle dispersion containing lactam compound
US7244765B2 (en) * 2004-06-25 2007-07-17 Cytokine Pharmasciences, Inc Guanylhydrazone salts, compositions, processes of making and methods of using
US20060069136A1 (en) * 2004-09-24 2006-03-30 Ulrich Klar Use of Epothilones in the treatment of bone metastasis
KR20070084325A (ko) * 2004-11-18 2007-08-24 브리스톨-마이어스 스큅 컴퍼니 익사베필론을 포함하는 장용성 코팅된 비드 및 그의 제조방법
EP1824458A1 (en) * 2004-11-18 2007-08-29 Bristol-Myers Squibb Company Enteric coated bead comprising epothilone or an epothilone analog, and preparation and administration thereof
AR057325A1 (es) * 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
US8642246B2 (en) 2007-02-26 2014-02-04 Honeywell International Inc. Compositions, coatings and films for tri-layer patterning applications and methods of preparation thereof
BRPI0911482A2 (pt) 2008-04-24 2017-08-29 Bristol Myers Squibb Co Uso de epotilona d no tratamento de doenças associadas a tau incluindo doenças de alzheimer
US8557877B2 (en) 2009-06-10 2013-10-15 Honeywell International Inc. Anti-reflective coatings for optically transparent substrates
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
US8864898B2 (en) 2011-05-31 2014-10-21 Honeywell International Inc. Coating formulations for optical elements
CN102276433B (zh) * 2011-06-30 2016-04-20 南昌大学 木豆素c及其衍生物及其在制备抗癌药物中的应用
WO2016167892A1 (en) 2015-04-13 2016-10-20 Honeywell International Inc. Polysiloxane formulations and coatings for optoelectronic applications

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4138042C2 (de) 1991-11-19 1993-10-14 Biotechnolog Forschung Gmbh Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel
DE19542986A1 (de) 1995-11-17 1997-05-22 Biotechnolog Forschung Gmbh Epothilon-Derivate und deren Verwendung
PT1186606E (pt) 1995-11-17 2004-08-31 Biotechnolog Forschung Mbh Gbf Derivados do epotilone sua preparacao e utilizacao
DE19639456A1 (de) 1996-09-25 1998-03-26 Biotechnolog Forschung Gmbh Epothilon-Derivate, Herstellung und Mittel
AU735900B2 (en) * 1996-03-12 2001-07-19 Pg-Txl Company, L.P. Water soluble paclitaxel prodrugs
US6441025B2 (en) * 1996-03-12 2002-08-27 Pg-Txl Company, L.P. Water soluble paclitaxel derivatives
NZ334821A (en) 1996-08-30 2000-12-22 Novartis Ag Method for producing epothilones
DE19645361A1 (de) 1996-08-30 1998-04-30 Ciba Geigy Ag Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B, Teil II
DE19645362A1 (de) 1996-10-28 1998-04-30 Ciba Geigy Ag Verfahren zur Herstellung von Epothilon A und B und Derivaten
DE19636343C1 (de) * 1996-08-30 1997-10-23 Schering Ag Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B
DK1367057T3 (da) 1996-11-18 2009-01-19 Biotechnolog Forschung Gmbh Epothiloner E og F
US6515016B2 (en) 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
CA2273083C (en) * 1996-12-03 2012-09-18 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6204388B1 (en) 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
US6380394B1 (en) 1996-12-13 2002-04-30 The Scripps Research Institute Epothilone analogs
DE19701758A1 (de) 1997-01-20 1998-07-23 Wessjohann Ludgar A Dr Epothilone-Synthesebausteine
CN1544436A (zh) 1997-02-25 2004-11-10 ���＼���о����޹�˾��GBF�� 3，7-保护的环氧噻嗪酮-n-氧化物及其制备方法
DE19713970B4 (de) 1997-04-04 2006-08-31 R&D-Biopharmaceuticals Gmbh Epothilone-Synthesebausteine II - Prenylderivate
US6348551B1 (en) 1997-04-18 2002-02-19 Studiengesellschaft Kohle Mbh Selective olefin metathesis of bifunctional or polyfunctional substrates in compressed carbon dioxide as reaction medium
DE19821954A1 (de) 1997-05-15 1998-11-19 Biotechnolog Forschung Gmbh Verfahren zur Herstellung eines Epothilon-Derivats
DE19720312A1 (de) 1997-05-15 1998-11-19 Hoechst Ag Zubereitung mit erhöhter in vivo Verträglichkeit
DE19726627A1 (de) 1997-06-17 1998-12-24 Schering Ag Zwischenprodukte, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung von Epothilon
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
DK1001951T3 (da) 1997-07-16 2002-12-23 Schering Ag Thiazolderivater, fremgangsmåde til fremstilling deraf og anvendelse af disse
US7407975B2 (en) 1997-08-09 2008-08-05 Bayer Schering Pharma Ag Epothilone derivatives, method for producing same and their pharmaceutical use
US6365749B1 (en) 1997-12-04 2002-04-02 Bristol-Myers Squibb Company Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
NZ506389A (en) 1998-02-05 2003-07-25 Novartis Ag Pharmaceutical compositions containing epothilone which can be optionally lyophilised
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
CA2322157C (en) 1998-02-25 2012-05-29 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
FR2775187B1 (fr) * 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
US6399638B1 (en) 1998-04-21 2002-06-04 Bristol-Myers Squibb Company 12,13-modified epothilone derivatives
AU5036999A (en) 1998-06-30 2000-01-17 Schering Aktiengesellschaft Epothilon derivatives, their preparation process, intermediate products and their pharmaceutical use
EP1135470A2 (en) 1998-11-20 2001-09-26 Kosan Biosciences, Inc. Recombinant methods and materials for producing epothilone and epothilone derivatives
CA2352505C (en) 1998-12-22 2009-04-07 Novartis Ag Epothilone derivatives and their use as antitumor agents
PL349863A1 (en) 1999-02-18 2002-09-23 Schering Ag 16-halogen-epothilone derivatives, method for producing them and their pharmaceutical use
US6211412B1 (en) 1999-03-29 2001-04-03 The University Of Kansas Synthesis of epothilones
AR023792A1 (es) 1999-04-30 2002-09-04 Bayer Schering Pharma Ag Derivados 6-alquenilo- y 6-alquinilo-epotilona, los procedimientos para prepararlos y su empleo en productos farmaceuticos
WO2002058699A1 (en) 2001-01-25 2002-08-01 Bristol-Myers Squibb Company Pharmaceutical forms of epothilones for oral administration
MXPA03006412A (es) 2001-01-25 2003-10-15 Bristol Myers Squibb Co Metodos para administrar analogos de epotilona para tratamiento de cancer.
EP1383490B1 (en) 2001-03-14 2012-04-25 Bristol-Myers Squibb Company Combination of an epothilone analog and chemotherapeutic agents for the treatment of proliferative diseases

Also Published As

Publication number Publication date
BR0206695A (pt) 2004-04-20
HUP0303800A3 (en) 2005-02-28
EP1361877A1 (en) 2003-11-19
YU58103A (sh) 2006-03-03
UY27138A1 (es) 2002-08-30
HUP0303800A2 (hu) 2004-03-29
TWI250017B (en) 2006-03-01
NO20033343D0 (no) 2003-07-24
IS6892A (is) 2003-07-24
CA2434584A1 (en) 2002-08-01
US6576651B2 (en) 2003-06-10
MXPA03006476A (es) 2003-09-22
AR035078A1 (es) 2004-04-14
WO2002058701A1 (en) 2002-08-01
RU2003126174A (ru) 2005-02-27
NZ526871A (en) 2006-01-27
PL368636A1 (en) 2005-04-04
US20020177615A1 (en) 2002-11-28
PE20020853A1 (es) 2002-09-27
JP2004528287A (ja) 2004-09-16
EE200300329A (et) 2003-10-15
CN1498106A (zh) 2004-05-19
SK9212003A3 (en) 2004-11-03
KR20040025888A (ko) 2004-03-26
AU2002253880B2 (en) 2006-11-09
HRP20030674A2 (en) 2005-06-30
USRE40387E1 (en) 2008-06-17
RU2291695C2 (ru) 2007-01-20
CN1268336C (zh) 2006-08-09
IL156759A0 (en) 2004-02-08
BG108027A (bg) 2004-12-30
CZ20032023A3 (cs) 2005-03-16
WO2002058699A1 (en) 2002-08-01

Similar Documents

Publication Publication Date Title
NO20033343D0 (no) Farmasöytiske doseringsformer av epothiloner for oral administrasjon
PL356358A1 (en) Solid dosage form of someticone for oral administration
CY2018005I2 (el) Απο του στοματος φαρμακοτεχνικες μορφες της κλαντριβινης
NO20034689L (no) Farmasöytiske doseringsformer av amorf nelfinavir mesylat
IL166489A (en) Oral dosage form in single-dose administration containing at least two layers for the administration and use of flipridone
HRP20040545A2 (en) Pharmaceutical compositions of orally active taxane derivatives having enhanced bioavailability
NO20004823D0 (no) Nye galeniske formuleringer av meloksicam for oral administrering
IL162843A0 (en) Dosage form for oral administration of a pde4 inhibitor
NO20020976L (no) Retarderte, orale, farmasöytiske administreringsformer
NO20042842L (no) Farmasoytiske formuleringer av platina-derivat
NO20035438L (no) Farmasoytisk formulering for effektiv administrering av apomorfin, 6aR-(-)-N-propyl-norapomorfin og deres derivater og prodrugs derav
DE60317803D1 (de) Pharmazeutische zusammensetzungen enthaltend cyclosporin zur oralen verabreichung
PL372773A1 (en) Oral administration of epothilones
NO20014738D0 (no) Tolperisonholdig farmasöytisk preparat for oral administrering
FI20000780A (fi) Peroraalinen lääkemuoto lääkeaineen hallituksi vapauttamiseksi
EE200300501A (et) Ninna manustatavad imidasotriasinooni sisaldavad kompositsioonid
NO20040047L (no) Farmasoytisk formulering for intramuskulaer administrering av fulvestrant
NO20025394D0 (no) Formuleringer inneholdende et glukokorticoid legemiddel for behandling av bronkopulmonire sykdommer
NO20043007L (no) Farmasoytisk suspensjon for oral administrering
HK1102021A1 (en) Pharmaceutical composition for oral administration of a pyrazol-3- carboxamide derivative
NO20050183L (no) Farmasoytiske salter av reboxetin
NO20043633L (no) Oral doseringsform for kontrollert medikamentfrigivning
NO20032581D0 (no) Farmasöytisk formulering av gepiron for oral administrering
EP1361866A4 (en) EMULSIONS AS SOLID DOSAGE FORMS FOR ORAL ADMINISTRATION
AU2002348105A1 (en) Oral dosage forms for improving the bioavailability of therapeutic agents

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application